Table 4.
Implant Dosimetry achieved for all patients, those with a recognizable DIL on pathology and those without a DIL. Values are given as median (Inter-Quartile-Range).
| Dosimetric Value | All Patients [n = 455] | DIL present [n = 396] | No DIL present [n = 59] | p-value∗ |
|---|---|---|---|---|
| Needles | 28 (26–30) | 28 (26–30) | 28 (26–30) | 0.53 |
| Seeds | 75 (67–84) | 75 (67–84) | 77 (70–84) | 0.63 |
| Activity [U] | 0.56 (0.56–0.56) | 0.56 (0.56–0.56) | 0.56 (0.56–0.56) | 0.15 |
| Prostate Volume [cc] | 34.3 (28.2–41.1) | 34.2 (27.8–41.2) | 35.1 (30.0–40.7) | 0.73 |
| Prostate V100 [%] | 98.6 (97.8–99.8) | 98.6 (97.8–99.3) | 98.7 (97.8–99.5) | 0.34 |
| Prostate V150 [%] | 77.8 (75.6–79.8) | 77.9 (75.7–79.8) | 77.1 (75.1–79.2) | 0.09 |
| Prostate V200 [%] | 44.4 (40.8–47.5) | 44.4 (40.8–47.6) | 44.3 (40.6–46.8) | 0.30 |
| Prostate D90 [Gy] | 189.8 (184.7–193.5) | 189.8 (184.7–193.5) | 189.4 (183.6–193.8) | 0.70 |
| Urethra V140 [cc] | 16.1 (10.5–20.0) | 16.1 (10.6–20.0) | 16.0 (10.7–19.9) | 0.95 |
| Urethra V150 [cc] | 0.15 (0.00–0.68) | 0.15 (0.00–0.63) | 0.23 (0.00–0.72) | 0.72 |
∗Mann-Whitney-Wilcoxon was used between groups with and without DIL.